medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2012, Número 3

<< Anterior Siguiente >>

Arch Neurocien 2012; 17 (3)


Migraña

Melo-Carrillo A, López-Ávila A

Idioma: Español
Referencias bibliográficas: 88
Paginas: 172-178
Archivo PDF: 107.26 Kb.


RESUMEN

La migraña es una patología neurovascular común caracterizada por céfalea intensa que afecta a miles de personas perjudica de manera significativa su bienestar biopsicosocial. A pesar de ser una patología común, poco es lo que se conoce acerca de ella. El objetivo de esta revisión es exponer el panorama actual en el estudio de la migraña. Se discutirán las principales hipótesis acerca de su génesis, líneas de investigación básicas y clínicas encaminadas a aclarar la fisiopatología; así como, avances farmacológicos y no farmacológicos recién descritos para su tratamiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ferrari MD. Migraine. Lancet 1998;351:1043-52.

  2. Pietrobon D, Striessing J, Neurobiology of migraine. Nat Rev Neurosci 2003;45:386-98.

  3. The International Classification of headache disorders. Cephalalgia 2004.

  4. Goadsby PJ. Neurovascular Headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine. Cephalalgia 2002;22:107-11.

  5. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current Understanding and treatment. 2002,346:257-71.

  6. Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 1995;15:277-80.

  7. Lauritzen M. Pathophysiology of the migraine aura: the spreadindg depression theory. Brain 1994; 117: 199-210.

  8. Akerman S, Williamson DJ, Hill RG, Goadsby PJ. The effect of adrenergic compounds on neurogenic dural vasodilatation. Eur J Pharmacol 2001;424:53-8.

  9. DaSilva AFM, Becerra L, Makris N, Strassman AM, et al. Somatotopic Activation in the Human Trigeminal Pain Pathway. J Neurosci 2002, 22(18): 8183-92.

  10. Lipton RB, Diamond S, Reed M, Diamond MI, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638-45.

  11. Schoenen J. Clinical neurophysiology of headache. In: Mathew NT, ed. Neurologic clinics. Philadelphia: Saunders Company, 1997.

  12. Akerman S, Goadsby PJ. The role of dopamine in a model of trigeminovascular nociception. JPET 2005, 314: 162-9.

  13. Akerman S, Williamson DJ, Kaue H, Goadsby PJ. The role of histamine in dural vessel dilation. Brain Research 2002, 956: 96-102.

  14. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol 2002;452:223-8.

  15. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004, 55:19-26.

  16. Burnstein R, Jakubowski M. Analgesic Triptan Action in an Animal Model of Intracranial Pain: A race against the Development of Central Sensitization. Ann Neurol 2004, 55: 27-36.

  17. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89:107-10.

  18. Lauritzen M. Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 1983;13: 633-41.

  19. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7:359-90.

  20. Uwe Reuter, Hayrunnisa Bolay, Inger Jansen-Olesen, et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001;124:2490-502.

  21. Hayrunnisa Bolay, Uwe Reuter, Andrew K. Dunn, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Medicine 2002;9:136-42.

  22. Van Der Kamp, Maassen Van Den Brink A, Ferrari Md. Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation. J Neurol Sci 1996;139:106-10.

  23. Welch KMA. Migraine-related stroke in the context of the IHSC of head pain. Arch Neruol 1990;47:458-62.

  24. Welch KMA. Drug therapy of migraine. N Eng J Med 1993; 329:1476-83.

  25. Welch KMA, Mathew NT. Stone P, Rosamond W, Saiers J, Gutterman. Tolerability of sumatriptan: clinical trials and postmarketing experience. Cephalalgia 2001; 21:164-5.

  26. Haan J, Terwindt GM, Ferrari MD. Genetics of migraine. In: Mathew NT, ed. Neurologic clinics. Philadelphia Saunders, 1996.

  27. Ophoff RA, van den Maagdenberg AMJM, Roon KI, Ferrari MD, Frants RR. The impact of pharmacogenetics for migraine. Eur J Pharmacol 2001;413:1-10.

  28. Weiller C, May A, limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-60.

  29. Lance JW, Goasby PJ. Mechanism and management of headache. 6th edition. Boston: Butterworth Heinemann, 1998.

  30. Olesen J, Tfelt-Hansen P, Welch KMA. The headaches 2nd ed. Philadelphia. Lippincou Williams & Wilkins, 2000.

  31. Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. Cephalalgia 2004,24:321-32.

  32. Wilkinson M. Migraine and cluster headache: their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995;15:337-57.

  33. Silberstein SD, Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996; 36: 547-55.

  34. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurol 2000;54:1553.

  35. Connor HE, Feniuk W, Beattle DT, North PC, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997;17:145-52.

  36. Diener HC, Tfelt-Hansen P, Beukelaar F, Ferrari MD, et al. The efficacy and safety of sc Alniditan vs. sc Sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Chepalalgia 2001;21:672-9.

  37. Dodick DW, Mar tin V. Triptans and CNS side-ef fects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004;24:417-24.

  38. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological and pharmacokinetic properties of triptans. Headache 2003;43:376-88.

  39. Ottani A, Ferraris E, Giuliani D, Mioni C, et al. Effect of sumatriptan in different models of pain in rats. Eur J Pharmacol 2004;497:181-6.

  40. Terence Fullerton, Denise Komorowski-Swiatek, Allan Forrest, Fran M Gengo. The pharmacodynamics of Sumatriptan in Nitroglycerin-Induced Headache. J Clin Pharmacol 1999;39: 17-29.

  41. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. PNAS 2004, 101: 4272-9.

  42. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 2004;24:611-22.

  43. Potter DL, Hart De, Calder CS, Storey JR. Ad double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology 2000;54: Suppl 3:A15.

  44. Stephen J. Peroutka. Migraine: a chronic sympathetic nervous system disorder. Headache 2004;44:53-64.

  45. Ferrari MD. Migraine. Lancet 1998;351:1043-52.

  46. Pietrobon D, Striessing J, Neurobiology of migraine. Nat Rev Neurosci 2003;45:386-98.

  47. The International Classification of headache disorders. Cephalalgia 2004.

  48. Goadsby PJ. Neurovascular Headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine. Cephalalgia 2002;22:107-11.

  49. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current Understanding and treatment. 2002,346:257-71.

  50. Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 1995;15:277-80.

  51. Lauritzen M. Pathophysiology of the migraine aura: the spreadindg depression theory. Brain 1994; 117: 199-210.

  52. Akerman S, Williamson DJ, Hill RG, Goadsby PJ. The effect of adrenergic compounds on neurogenic dural vasodilatation. Eur J Pharmacol 2001;424:53-8.

  53. DaSilva AFM, Becerra L, Makris N, Strassman AM, et al. Somatotopic Activation in the Human Trigeminal Pain Pathway. J Neurosci 2002, 22(18): 8183-92.

  54. Lipton RB, Diamond S, Reed M, Diamond MI, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638-45.

  55. Schoenen J. Clinical neurophysiology of headache. In: Mathew NT, ed. Neurologic clinics. Philadelphia: Saunders Company, 1997.

  56. Akerman S, Goadsby PJ. The role of dopamine in a model of trigeminovascular nociception. JPET 2005, 314: 162-9.

  57. Akerman S, Williamson DJ, Kaue H, Goadsby PJ. The role of histamine in dural vessel dilation. Brain Research 2002, 956: 96-102.

  58. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol 2002;452:223-8.

  59. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004, 55:19-26.

  60. Burnstein R, Jakubowski M. Analgesic Triptan Action in an Animal Model of Intracranial Pain: A race against the Development of Central Sensitization. Ann Neurol 2004, 55: 27-36.

  61. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89:107-10.

  62. Lauritzen M. Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 1983;13: 633-41.

  63. Leao AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7:359-90.

  64. Uwe Reuter, Hayrunnisa Bolay, Inger Jansen-Olesen, et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001;124:2490-502.

  65. Hayrunnisa Bolay, Uwe Reuter, Andrew K. Dunn, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Medicine 2002;9:136-42.

  66. Van Der Kamp, Maassen Van Den Brink A, Ferrari Md. Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation. J Neurol Sci 1996;139:106-10.

  67. Welch KMA. Migraine-related stroke in the context of the IHSC of head pain. Arch Neruol 1990;47:458-62.

  68. Welch KMA. Drug therapy of migraine. N Eng J Med 1993; 329:1476-83.

  69. Welch KMA, Mathew NT. Stone P, Rosamond W, Saiers J, Gutterman. Tolerability of sumatriptan: clinical trials and postmarketing experience. Cephalalgia 2001; 21:164-5.

  70. Haan J, Terwindt GM, Ferrari MD. Genetics of migraine. In: Mathew NT, ed. Neurologic clinics. Philadelphia Saunders, 1996.

  71. Ophoff RA, van den Maagdenberg AMJM, Roon KI, Ferrari MD, Frants RR. The impact of pharmacogenetics for migraine. Eur J Pharmacol 2001;413:1-10.

  72. Weiller C, May A, limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-60.

  73. Lance JW, Goasby PJ. Mechanism and management of headache. 6th edition. Boston: Butterworth Heinemann, 1998.

  74. Olesen J, Tfelt-Hansen P, Welch KMA. The headaches 2nd ed. Philadelphia. Lippincou Williams & Wilkins, 2000.

  75. Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. Cephalalgia 2004,24:321-32.

  76. Wilkinson M. Migraine and cluster headache: their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995;15:337-57.

  77. Silberstein SD, Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996; 36: 547-55.

  78. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurol 2000;54:1553.

  79. Connor HE, Feniuk W, Beattle DT, North PC, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997;17:145-52.

  80. Diener HC, Tfelt-Hansen P, Beukelaar F, Ferrari MD, et al. The efficacy and safety of sc Alniditan vs. sc Sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Chepalalgia 2001;21:672-9.

  81. Dodick DW, Mar tin V. Triptans and CNS side-ef fects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004;24:417-24.

  82. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological and pharmacokinetic properties of triptans. Headache 2003;43:376-88.

  83. Ottani A, Ferraris E, Giuliani D, Mioni C, et al. Effect of sumatriptan in different models of pain in rats. Eur J Pharmacol 2004;497:181-6.

  84. Terence Fullerton, Denise Komorowski-Swiatek, Allan Forrest, Fran M Gengo. The pharmacodynamics of Sumatriptan in Nitroglycerin-Induced Headache. J Clin Pharmacol 1999;39: 17-29.

  85. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. PNAS 2004, 101: 4272-9.

  86. Edvinsson L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 2004;24:611-22.

  87. Potter DL, Hart De, Calder CS, Storey JR. Ad double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology 2000;54: Suppl 3:A15.

  88. Stephen J. Peroutka. Migraine: a chronic sympathetic nervous system disorder. Headache 2004;44:53-64.




2020     |     www.medigraphic.com